None
Quote | Protagenic Therapeutics Inc. (OTCMKTS:PTIX)
Last: | $2.24 |
---|---|
Change Percent: | -39.62% |
Open: | $3.0877 |
Close: | $2.24 |
High: | $3.0877 |
Low: | $2.2 |
Volume: | 3,051,649 |
Last Trade Date Time: | 04/27/2021 04:55:58 pm |
News | Protagenic Therapeutics Inc. (OTCMKTS:PTIX)
2024-04-23 13:16:54 ET More on Mid-day movers & stocks. Kopin Corporation (KOPN) Q4 2023 Earnings Call Transcript Cemtrex, Inc. (CETX) Q1 2024 Earnings Call Transcript Kopin GAAP EPS of -$0.06 misses by $0.03, revenue of $8.6M misses by $0.43M Cemtrex GAA...
Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a tal...
Message Board Posts | Protagenic Therapeutics Inc. (OTCMKTS:PTIX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $PTIX News Article - Protagenic Therapeutics Announces Second Quarter 2021 Results and | whytestocks | investorshangout | 08/17/2021 5:50:47 PM |
whytestocks: $PTIX News Article - Best Biotech Penny Stocks in June 2021? Check These 4 Out | whytestocks | investorshangout | 05/26/2021 2:00:49 PM |
znewcar1: PTIX 28% v5,0M c2.72 f14,6M H3.1 | znewcar1 | investorshangout | 05/25/2021 9:23:59 PM |
znewcar1: PTIX 53% v125M c3.27 f13,7M H4.89 morning pop with afternoon chop R@4 | znewcar1 | investorshangout | 05/11/2021 1:39:11 AM |
whytestocks: $PTIX News Article - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers | whytestocks | investorshangout | 05/10/2021 2:10:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Protagenic Therapeutics Inc. Company Name:
PTIX Stock Symbol:
OTCMKTS Market:
Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a tal...
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023 Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portion Plans to enroll final tw...
Next clinical progress update expected in April 2024 NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. The ...